Get the Stockscreener App
0.2417
7.92%
-0.0208
Pre-market:
.24
-0.0017
-0.70%
Outlook Therapeutics Inc stock is traded at $0.2417, with a volume of 5.32M.
It is down -7.92% in the last 24 hours and up +10.37% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$0.2625
Open:
$0.259
24h Volume:
5.32M
Relative Volume:
1.67
Market Cap:
$29.18M
Revenue:
$297.50K
Net Income/Loss:
$-72.19M
P/E Ratio:
-0.1411
EPS:
-1.7127
Net Cash Flow:
$-54.39M
1W Performance:
-7.78%
1M Performance:
+10.37%
6M Performance:
-80.66%
1Y Performance:
-84.41%
1-Day Range:
$0.238
$0.2602
1-Week Range:
$0.238
$0.2761
52-Week Range:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.2417 | 29.18M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
OTLK Technical Analysis | Trend, Signals & Chart Patterns | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Reports Closing of $5.0 Million Registered Direct Offering - VisionMonday.com
Outlook Therapeutics launches public offering; shares down - MSN
OTLK Price Today: Outlook Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Certain Options of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Outlook Therapeutics (OTLK) joint holders report 4.99% stake after SPA - Stock Titan
Outlook Therapeutics closes $5M registered direct offering By Investing.com - Investing.com India
Outlook Therapeutics stock slides after pricing $5M offering - MSN
Outlook Therapeutics announces $5M registered direct offering priced at-the-market - MSN
Outlook Therapeutics Announces New Equity Financing Transaction - TipRanks
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics closes $5M registered direct offering - Investing.com
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - The Manila Times
Outlook Therapeutics (NASDAQ: OTLK) raises $5M via 16.13M-share deal - Stock Titan
Outlook Therapeutics raises $5M in registered direct offering By Investing.com - Investing.com India
Outlook Therapeutics drops 17%, prices $13M stock offering - MSN
Outlook Therapeutics Inc. posts 24.4% EPS miss, $1.4T revenueVerified Stock Signals - Xã Thanh Hà
Outlook Therapeutics (OTLK) Announces $5M Share Offering - GuruFocus
Outlook Therapeutics raises $5M in registered direct offering - Investing.com
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Outlook sells 16.1M shares at 31 cents to raise $5M in direct sale - Stock Titan
Outlook Therapeutics completes FDA dispute resolution meeting By Investing.com - Investing.com India
Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug - TipRanks
Outlook Therapeutics (OTLK) Advances Regulatory Discussions with FDA - GuruFocus
Outlook Therapeutics completes FDA Federal Dispute Resolution meeting for ONS-5010; formal decision expected May 2026 - TradingView
Outlook Therapeutics (OTLK) finishes FDA FDR meeting; ONS-5010 decision expected May 2026 - Stock Titan
Outlook Therapeutics completes FDA dispute resolution meeting - Investing.com
Outlook Therapeutics completes federal dispute resolution (FDR) meeting with FDA for ONS-5010/Lytenava(TM) (bevacizumab-vikg) - marketscreener.com
Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg) - TradingView
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - ChartMill
OTLK | Outlook Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakouts Watch: Will Outlook Therapeutics Inc benefit from AI trends2026 Big Picture & Low Drawdown Trading Strategies - baoquankhu1.vn
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Hold Rating, Maintains Target Price $0.5 - Moomoo
Outlook Therapeutics files dispute resolution request with FDA By Investing.com - Investing.com India
Outlook Therapeutics’ Formal Dispute Resolution for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA for Wet AMD Approval Pathway 1 - Minichart
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - Sahm
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Sahm
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010 - TipRanks
FDA accepts Outlook Therapeutics (NASDAQ: OTLK) dispute request on LYTENAVA - Stock Titan
Outlook Therapeutics request for FDA dispute resolution on ONS-5010 accepted - Traders Union
Outlook Therapeutics (OTLK) Seeks FDA Review for ONS-5010 Approval - GuruFocus
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):